We are live on ! Find out more
MG

Michael Gelband ExodusPoint Capital Management

AUM $15.5B
1-Year Est. Return 38.81%
 

Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.

This Fund
S&P 500
This Quarter Est. Return
+10.63%
1 Year Est. Return
+38.81%
3 Year Est. Return
+110.53%
5 Year Est. Return
+124.16%
10 Year Est. Return
AUM
$15.2B
AUM Growth
+$4.78B
Cap. Flow
+$3.57B
Cap. Flow %
23.39%
Top 10 Hldgs %
44.86%
Holding
2,187
New
553
Increased
436
Reduced
404
Closed
789

Top Sells

Rank Stock Value
1
VMW
VMware, Inc
VMW
+$95.7M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$89.4M
3
XOM icon
ExxonMobil
XOM
+$84.7M
4
SO icon
Southern Company
SO
+$79.2M
5
EMR icon
Emerson Electric
EMR
+$61.3M

Sector Composition

Rank Sector Weight
1 Technology 9.26%
2 Industrials 7.84%
3 Utilities 7.6%
4 Healthcare 5.4%
5 Real Estate 4.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IRON icon
1751
Disc Medicine
IRON
$3.06B
-25,330
Closed -$1.19M
IT icon
1752
Gartner
IT
$12.4B
-19,654
Closed -$6.75M
ITT icon
1753
ITT
ITT
$18.6B
-4,078
Closed -$399K
ITW icon
1754
Illinois Tool Works
ITW
$80.4B
-7,614
Closed -$1.75M
IVZ icon
1755
Invesco
IVZ
$14.1B
-24,708
Closed -$359K
JBLU icon
1756
JetBlue
JBLU
$1.85B
-273,615
Closed -$1.26M
JELD icon
1757
JELD-WEN Holding
JELD
$200M
-34,355
Closed -$459K
JETS icon
1758
CALL
US Global Jets ETF
JETS
$804M
-105,000
Closed -$1.79M
JPM icon
1759
JPMorgan Chase
JPM
$935B
-48,254
Closed -$7M
JPM icon
1760
PUT
JPMorgan Chase
JPM
$935B
-96,000
Closed -$13.9M
KALU icon
1761
Kaiser Aluminum
KALU
$2.52B
-11,443
Closed -$861K
KALV
1762
DELISTED
KalVista Pharmaceuticals
KALV
-34,393
Closed -$331K
KDP icon
1763
Keurig Dr Pepper
KDP
$43.6B
-32,881
Closed -$1.04M
KEX icon
1764
Kirby Corp
KEX
$7.39B
-266,270
Closed -$22M
KEY icon
1765
KeyCorp
KEY
$23.3B
-597,508
Closed -$6.43M
KFRC icon
1766
Kforce
KFRC
$1.05B
-6,073
Closed -$362K
KIDS icon
1767
OrthoPediatrics
KIDS
$670M
-10,194
Closed -$326K
KIM icon
1768
Kimco Realty
KIM
$16.1B
-1,040,807
Closed -$18.3M
NXDR
1769
Nextdoor Holdings
NXDR
$925M
-48,489
Closed -$88K
KKR icon
1770
KKR & Co
KKR
$97.4B
-30,552
Closed -$1.88M
KLAC icon
1771
KLA
KLAC
$240B
-105,200
Closed -$4.83M
KMX icon
1772
CarMax
KMX
$8.82B
-31,338
Closed -$2.22M
KNTK icon
1773
Kinetik
KNTK
$4.38B
-34,012
Closed -$1.15M
KPTI icon
1774
Karyopharm Therapeutics
KPTI
$44.5M
-93,170
Closed -$1.87M
KREF
1775
KKR Real Estate Finance Trust
KREF
$487M
-50,270
Closed -$597K

Similar funds

Michael Gelband's Q4 2023 Portfolio in Review

As of Q4 2023, Michael Gelband held 2,187 positions worth $15.2B, up 46% from $10.5B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Michael Gelband deployed $3.57B of net new capital in Q4 2023, opening 553 new positions and adding to 436 existing holdings. Its largest new stake was Fidelity National Information Services: 6,650,397 shares worth $399M.

By sector, the portfolio is most concentrated in Technology at 9.3% of assets, down from 10% a quarter earlier, followed by Industrials and Utilities.

On the sell side, the largest reduction was Merck, an estimated $48.2M trimmed.

  • Michael Gelband's largest Q4 2023 buy was Fidelity National Information Services: 6,650,397 shares worth $399M.
  • Michael Gelband added most to Global Payments in Q4 2023, an estimated $250M increase.
  • Michael Gelband's biggest Q4 2023 reduction was Merck, cutting an estimated $48.2M.
  • Michael Gelband fully exited VMware, Inc in Q4 2023, selling an estimated $95.7M.
  • Michael Gelband's ten largest holdings make up 45% of its $15.2B portfolio in Q4 2023.
  • Michael Gelband opened 553 new positions and closed 789 in Q4 2023.
  • Michael Gelband's portfolio value rose 46% quarter-over-quarter to $15.2B.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.